Cvrx, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021 and First Quarter and Full Year of 2022
January 10, 2022 at 06:30 pm IST
Share
CVRx, Inc. provides preliminary revenue guidance for the fourth quarter and full year of 2021 and first quarter and full year of 2022
. For the quarter of 2021, the company expects total revenue to be range of approximately $3.6 million to $3.7 million, representing an increase of approximately 71% to 77% over fourth quarter 2020 revenue of $2.1 million.
For the full year of 2021, the company expects total revenue to be in the range of approximately $13.0 million to $13.1 million, representing an increase of approximately 113% to 116% over full year 2020 revenue of $6.1 million.
For the first quarter of 2022, the Company expects total revenue between $3.6 million and $4.0 million.
For the full year 2022, the company expects total revenue to be between $20.0 million and $23.0 million.
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
CVRX, INC. 
